U.S. says J&J arthritis drug promotion misleading

	Tweet

A Johnson & Johnson promotion for rheumatoid arthritis drug Remicade is misleading because it makes unsupported claims about the drug’s effectiveness and omits important information about risks, U.S. regulators said in a letter released on Monday.

The Food and Drug Administration told the company to immediately stop using materials that contain the misleading information.

An eight-page sales material presented to doctors “suggests Remicade is safer and more effective than has been demonstrated by substantial evidence or clinical experience,” the FDA said in a letter dated Feb. 11 and posted on the agency’s Web site on Monday.

Michael Parks, a spokesman for Johnson & Johnson unit Centocor that makes Remicade, said the company was reviewing the letter and “will work with the FDA to resolve any issues.”

Johnson & Johnson shares fell 65 cents, or about 1 percent, in afternoon trading on the New York Stock Exchange. 

RELATED STORIES:
With Vioxx gone, pain drug prices jump   FDA approves automated hepatitis C virus assay on ADVIA Centaur Immunoassay system   FDA grants fast track status for ViroPharma’s Maribavir   FDA approves Implanon (etonogestrel implant) contraceptive   Celebrex not as bad for heart as Vioxx   Consumer ads pump up prescription drug costs   Congress told FDA failed public on Vioxx   Takeda may extend sleeping pill’s use for AD   New FDA report says earlier meetings w/FDA make drug review process more efficient   Novartis diabetes drug effective in combo study   Packaging matters in sticking with medicine   “Miracle” Cancer Drug Gleevec Can be Toxic to the Heart

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]